Applied DNA Sciences Contracts With Inventionland

STONY BROOK, NY--(Marketwire - Sep 18, 2012) - Applied DNA Sciences, Inc. ( OTCBB : APDN ), (Twitter: @APDN), a provider of DNA-based anti-counterfeiting technology and product authentication solutions, announced today that it has entered into a Development Agreement with Inventionland Corporation.The two companies will collaborate on the development of innovative loss-prevention products, based upon APDN's botanical DNA-marking platform. Inventionland will participate in product development with APDN and take the resultant new products and applications to its customers.

The agreement between APDN and Inventionland follows closely the launch by APDN of smartDNA, a system designed to mark offenders and to prevent theft. The system has been deployed internationally to protect banks, retailers, jewelers and pharmacies. APDN also launched its digitalDNA platform this year that combines DNA-based security with secure-cloud technology, mobile computing and authentication on-the-fly.

Inventionland Corporation (www.Inventionland.com) is America's largest invention factory.Over 1,000 different retailers and on-line stores have sold its innovations.Inventionland builds 2,000-2,400 new product samples for corporations and retailers to review for their shelves each year.With some retailers facing large asset loss from their stores, Inventionland was asked to invent new products to help eliminate loss in a more innovative and effective manner.Inventionland's founder, George Davison, is an APDN stockholder.After Mr. Davison contacted APDN, both organizations began collaborating to offer a retailer solution that would help eliminate asset loss.

Mr. Davison, renowned for his novel approaches to product development, and himself the subject of a profile on the U.S. cable TV channel History (formerly The History Channel), stated: "I was a long-standing fan of Applied DNA Sciences' novel technology and enormous breadth of application, as well as Dr. Hayward's already-validated approach to managing biotechnology development.Inventionland is now pleased to be able to take this platform to our market-leading retailers."

Dr. Hayward commented: "Biotech companies can benefit from Inventionland's innovative approach and unmatchable speed-to-market. We are thrilled to partner with Inventionland on some very original and unique applications for DNA marking."

About Applied DNA Sciences

APDN is a provider of botanical-DNA based security and authentication solutions that can help protect products, brands and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. SigNature DNA and smartDNA, our principal anti-counterfeiting and product authentication solutions that essentially cannot be copied, provide a forensic chain of evidence and can be used to prosecute perpetrators.

The statements made by APDN may be forward-looking in nature.Forward-looking statements describe APDN's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN's SEC reports and filings, including our Annual Report on Form 10-K, filed on December 8, 2011 and our subsequent quarterly reports on Form 10-Q.APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.

About Inventionland Inventionland (http://www.inventionland.com) is America's largest invention factory, Inventionland, turns out 2,000-2,400 new inventions each year. Employees at Inventionland work in 16 unique themed sets, such as a shipwrecked pirate ship, a faux cave, a giant robot and a castle complete with turrets and drawbridge. The inspiring setting includes three running waterfalls, life-like trees and butterflies and chirping birds. In the rear of Inventionland is a red carpet that leads to a state-of-the art audio, video, and animation studio complete with sound room and one of the largest green screens in the tri-state area. Metalworking, woodworking, molding, laser cutting, prototyping, circuit board construction, and more take place in a state-of-the-art product sample construction facility. Hundreds of new ideas come to life every month at Inventionland, where Davison's award-winning team sets an example of America's can-do spirit and ingenuity.

More here:
Applied DNA Sciences Contracts With Inventionland

Posted in DNA

Purple corn compound may aid in developing future treatments for Type 2 diabetes, kidney disease

Public release date: 18-Sep-2012 [ | E-mail | Share ]

Contact: Donna Krupa dkrupa@the-aps.org American Physiological Society

BETHESDA, Md. (Sept. 18, 2012)Diabetic nephropathy is one of the most serious complications related to diabetes, often leading to end-stage kidney disease. Purple corn grown in Peru and Chile is a relative of blue corn, which is readily available in the U.S. The maize is rich in anthocyanins (also known as flavonoids), which are reported to have anti-diabetic properties. Scientists from the Department of Food and Nutrition and Department of Biochemistry at Hallym University in Korea investigated the cellular and molecular activity of purple corn anthocyanins (PCA) to determine whether and how it affects the development of diabetic nephropathy (DN). Their findings suggest that PCA inhibits multiple pathways involved in the development of DN, which may help in developing therapies aimed at type 2 diabetes and kidney disease.

The study is entitled "Purple corn anthocyanins inhibit diabetes-associated glomerular monocyte activation and macrophage infiltration" http://bit.ly/SlrkRY. It appears in the online edition of the American Journal of Physiology Renal Physiology, published by the American Physiological Society (APS; http://www.the-aps.org).

Methodology

Researcher Min-Kyung Kang and colleagues performed a two-part study, an in vitro experiment investigating the effects of PCA on human endothelial cells cultured under hyperglycemic kidney conditions and an in vivo study that investigated the effects of PCA on kidney tissue in diabetic mice. In the in vitro experiment, cultured cells were exposed to 1-20 g/ml of PCA for six hours (control cells were not exposed), then assessed for level of monocyte-endothelial cell adhesion, a major factor in the development of diabetic glomerulosclerosis. In the in vivo experiment, diabetic and control mice were dosed with PCA for eight weeks, then changes in kidney tissue were assessed and immunohistological analyses were performed. Kidney tissue was further analyzed for levels of inflammatory chemokines, which are key components in DN.

Results

Researchers found that in human endothelial cells cultured in hyperglycemic kidney conditions, induction of endothelial cell adhesion molecules decreased in a dose-dependent manner with PCA exposure, meaning that the PCA likely interfered with cell-cell adhesion in glomeruli. PCA also appeared to interfere with leukocyte recruitment and adhesion to glomerular endothelial cells. In diabetic mice, PCA exposure slowed mesangial expansion and interrupted the cellular signaling pathway that may instigate glomerular adhesion and infiltration of inflammatory cells responsible for diabetic glomerulosclerosis. Finally, PCA inhibited levels of macrophage inflammatory protein-2 and monocyte chemotactic protein-1 in kidney tissue, demonstrating that it may inhibit macrophage infiltration, which is closely related to renal inflammation.

Importance of the Findings

The research suggests that anthocyanins may be the main biofunctional compound in purple corn and could protect against mesangial activation of monocytes and infiltration of macrophages in glomerulithe two major contributors to DN. The research further suggests that renoprotection by PCA against mesangial activation may be specific therapies targeting diabetes-associated diabetic glomerulosclerosis and renal inflammation. Finally, PCA supplementation may be an important strategy in preventing renal vascular disease in type 2 diabetes.

Read the original here:
Purple corn compound may aid in developing future treatments for Type 2 diabetes, kidney disease

Compound found in purple corn may aid in developing future treatments for type 2 diabetes, kidney disease

ScienceDaily (Sep. 18, 2012) Diabetic nephropathy is one of the most serious complications related to diabetes, often leading to end-stage kidney disease. Purple corn grown in Peru and Chile is a relative of blue corn, which is readily available in the U.S. The maize is rich in anthocyanins (also known as flavonoids), which are reported to have anti-diabetic properties.

Scientists from the Department of Food and Nutrition and Department of Biochemistry at Hallym University in Korea investigated the cellular and molecular activity of purple corn anthocyanins (PCA) to determine whether and how it affects the development of diabetic nephropathy (DN). Their findings suggest that PCA inhibits multiple pathways involved in the development of DN, which may help in developing therapies aimed at type 2 diabetes and kidney disease.

The study is entitled "Purple corn anthocyanins inhibit diabetes-associated glomerular monocyte activation and macrophage infiltration." It appears in the online edition of the American Journal of Physiology -- Renal Physiology, published by the American Physiological Society.

Methodology

Researcher Min-Kyung Kang and colleagues performed a two-part study, an in vitro experiment investigating the effects of PCA on human endothelial cells cultured under hyperglycemic kidney conditions and an in vivo study that investigated the effects of PCA on kidney tissue in diabetic mice. In the in vitro experiment, cultured cells were exposed to 1-20 g/ml of PCA for six hours (control cells were not exposed), then assessed for level of monocyte-endothelial cell adhesion, a major factor in the development of diabetic glomerulosclerosis. In the in vivo experiment, diabetic and control mice were dosed with PCA for eight weeks, then changes in kidney tissue were assessed and immunohistological analyses were performed. Kidney tissue was further analyzed for levels of inflammatory chemokines, which are key components in DN.

Results

Researchers found that in human endothelial cells cultured in hyperglycemic kidney conditions, induction of endothelial cell adhesion molecules decreased in a dose-dependent manner with PCA exposure, meaning that the PCA likely interfered with cell-cell adhesion in glomeruli. PCA also appeared to interfere with leukocyte recruitment and adhesion to glomerular endothelial cells. In diabetic mice, PCA exposure slowed mesangial expansion and interrupted the cellular signaling pathway that may instigate glomerular adhesion and infiltration of inflammatory cells responsible for diabetic glomerulosclerosis. Finally, PCA inhibited levels of macrophage inflammatory protein-2 and monocyte chemotactic protein-1 in kidney tissue, demonstrating that it may inhibit macrophage infiltration, which is closely related to renal inflammation.

Importance of the Findings

The research suggests that anthocyanins may be the main biofunctional compound in purple corn and could protect against mesangial activation of monocytes and infiltration of macrophages in glomeruli -- the two major contributors to DN. The research further suggests that renoprotection by PCA against mesangial activation may be specific therapies targeting diabetes-associated diabetic glomerulosclerosis and renal inflammation. Finally, PCA supplementation may be an important strategy in preventing renal vascular disease in type 2 diabetes.

"PCA may be a potential renoprotective agent treating diabetes-associated glomerulosclerosis," wrote the researchers.

Go here to read the rest:
Compound found in purple corn may aid in developing future treatments for type 2 diabetes, kidney disease

Embryo-Critical Protein Modeled In 3D For First Time

Featured Article Academic Journal Main Category: Biology / Biochemistry Also Included In: Genetics;Cancer / Oncology Article Date: 18 Sep 2012 - 10:00 PDT

Current ratings for: Embryo-Critical Protein Modeled In 3D For First Time

Their findings are due to be published in a new journal called eLife, expected be launched this winter.

The team is led by biophysicist Eva Nogales, an electron microscopy expert with the US Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab) in Berkeley, California, and one of two corresponding authors on the journal paper.

"Our model should also be an invaluable tool for the design of new experiments aimed at asking detailed questions about the mechanisms that enable PRC2 to function and how those mechanisms might be exploited," says Nogales in a recent press statement.

For instance, mouse studies have shown deletion of any of its components either leads to death of the embryo or severe defects.

Scientists have also shown than PRC2 helps control differentiation of embryonic stem cells into other types of cell: the protein silences key genetic messages in the cell nucleus to effect this, as Nogales explains:

"PRC2 controls stem cell differentiation by regulating the expression of specific genes through the binding and methylation of histones, the proteins in chromatin that help bundle DNA into nucleosomes."

Such reasons are why the protein is what Nogales describes as one of the "top targets" for drug developers.

Nogales and colleagues produced their 3D model by painstakingly piecing together a jigsaw of data from many different sources, such as protein biochemistry, 3D electron microscopy, mass spectrometery, chemical cross-linking, and crystal structure docking.

Read the original here:
Embryo-Critical Protein Modeled In 3D For First Time

Wexford Online University Names Dr. Charles Foltz Professor with Focus on Science in Health and Fitness Field

Wexford Online University Names Dr. Charles Foltz Professor with Focus on Science in Health and Fitness Field

Dr. Charles Brown was recently named professor for Wexford University, where he will teach biochemistry, physiology and more with a focus on health and fitness. The 100 percent university offers a variety of health, exercise, sports and fitness degree programs of all levels to both U.S. and international students.

With a masters of Public Health in Epidemiology and doctorate in Interdisciplinary Molecular and Cellular Biology from Tulane University and a bachelors degree in Molecular Neuroscience from the University of California at Santa Barbara, Foltz is currently vice president of Research and Development at eHealth Screenings and senior project officer at Hip Hop Public Health. He is also the creator of 360 Cardio and has partnered with Polar heart rate monitors, the National Exercise and Sports Trainers Association (NESTA) and Total Health Interactive (THI). In addition, Foltz is a strength and conditioning coach and professional triathlon coach and manager. At Wexford University online, Foltz will teach subjects such as Biochemistry and Advanced Exercise Physiology with a focus on health and fitness for both local and international students.

Charles will offer Wexfords online students the perfect combination of science and real-world health and fitness experience and knowledge, said Jack Bauerle, Chancellor of Wexford University. He has worked with health and fitness organizations and individuals across the world, and were very pleased that hes bringing that wealth of wellness knowledge to Wexfords local and international students.

In addition, Foltz has earned certifications from the National Strength and Conditioning Association as a Certified Strength and Conditioning Coach and the National Academy of Sports Medicine as a Certified Performance Enhancement Specialist, a Certified Corrective Exercise Specialist and a Certified Personal Trainer.

Wexford University offers degree programs including an associate of arts degree in Fitness Training, a bachelor of science degree in Health and Fitness, a master of science degree in Nutrition and Exercise, a master of arts in Applied Sports Psychology and a doctorate degree in Applied Sports Psychology.

Wexford University is dedicated to providing world-class education through cutting-edge technology, offering direct application degree programs in an accelerated format with 100 percent online learning to save time and money. Programs include an associate of arts degree in Fitness Training, bachelors degree in Health and Fitness, masters degree in Nutrition and Exercise as well as masters degree and doctorate degree in Applied Sport Psychology. Wexford University is the higher education division of NESTA (National Exercise & Sports Trainers Association). For more information, please visit http://wexford.edu/.

See the original post:
Wexford Online University Names Dr. Charles Foltz Professor with Focus on Science in Health and Fitness Field

Large differences in lifetime physician earnings

SACRAMENTO A national study has found that earnings over the course of the careers of primary-care physicians averaged as much as $2.8 million less than the earnings of their specialist colleagues, potentially making primary care a less attractive choice for medical school graduates and exacerbating the already significant shortage of medical generalists.

The results, published online in the journal Medical Care, lead the study's authors to recommend reducing disparities in physician pay to ensure adequate access to primary care, which has been shown to improve health and reduce health-care costs.

"The need for primary-care providers is greater than ever before and expected to grow as millions more Americans become insured under the Affordable Care Act," said J. Paul Leigh, lead author of the study, professor of public health sciences and researcher with the UC Davis Center for Healthcare Policy and Research. "Without a better payment structure, there will be extraordinary demands on an already scarce resource."

According to projections by the Association of American Medical Colleges, the nation is likely to face a shortage of more than 65,000 primary-care physicians by 2025.

For the nationwide study, a follow-up to 2010 research by Leigh and his colleagues on differences in annual wages by specialty, the investigators compared lifetime earnings to demonstrate how annual wage differences accumulate over physicians' careers. The earnings data came from the 2004-05 Community Tracking Study, a periodic evaluation of physician demographic, geographic and market trends.

To ensure valid comparisons, the data were adjusted to account for factors that affect earnings, including age, sex, race, board certification, graduation from a foreign medical school, rural residence, employment by an academic medical school and residency program length.

Incomes were then evaluated for more than 6,000 doctors practicing in 41 specialties. When merged into four broad career categories, lifetime earnings in surgery, internal medicine and pediatric subspecialties, and all other medical specialties averaged from $761,402 to $1,587,722 higher than in primary care:

The earnings differences were more dramatic when compared as 41 separate specialties. Medical oncologists, for instance, earn up to $7,127,543 during a 35-year career, while family medicine practitioners earn as low as $2,838,637.

Leigh surmised that one reason for the earnings differences is the tendency for Medicare administrators to utilize recommendations from an American Medical Association committee on physician pay that price specialist procedures far higher than primary-care office visits. Private insurance companies, in turn, tend to adopt Medicare pay rates.

The authors noted that efforts are under way to resolve physician pay differences. For example, the Affordable Care Act requires states to pay primary-care physicians no less than 100 percent of Medicare payment rates for primary-care services provided to Medicaid patients. The study's senior author, Richard Kravitz, a UC Davis professor of internal medicine, also serves on an independent commission to assess physician pay.

Go here to see the original:
Large differences in lifetime physician earnings

Med school admits largest class ever

The Alpert Medical School welcomed its largest class ever this year totalling 120 students following the opening of the schools downtown facility last fall. With the building constructed in downtown Providences Knowledge District able to accommodate more students, the school matriculated 11 additional students in this years class, up from 109 in the class of 2015. The school has expanded from 310 students in 2001 to 421 students this year, according to Ed Wing, dean of medicine and biological sciences.

The admittance of the Med Schools largest-ever class was made possible by the new facility, Wing said. Admitting classes of 120 will expand the school to 480 students in the next few years, he said.

Its a terrific building, Wing said, adding that the schools old space in the BioMedical Center did not allow for expansion. Everything in the (new) building has allowed us to provide better education.

The Med School also witnessed a surge in applications for spots in the class of 2016, with a roughly 20 percent increase from 2,825 applicants in 2011 to 3,344 applications in 2012, according to Philip Gruppuso, associate dean of medical education and professor of pediatrics.

There is in general a physician shortage in the United States, Gruppuso said. He noted that the Association of American Medical Colleges has called for a substantial increase in the countrys supply of doctors and that the University is hoping to aid this goal. Gruppuso said the Med Schools expansion was part of a long-term process that occurred after administrators received permission from the Liaison Committee on Medical Education, the national accrediting organization for medical degree programs.

Wing said administrators have nothing definite planned to expand the student body any further than 480 students.

The Med School hired more staff to accommodate the larger building, but they did not need to hire more faculty members, Wing said, adding that the school boasts a total of 2,000 faculty members, including 600 full-time clinical faculty. The Med School revamped its curriculum but did not add additional classes or expand the size of courses.

Gruppuso said the University is still considered a small medical school according to national rankings of medical degree programs by size.

We had space and resources and faculty to be able to meet the needs of this number of students, he said. We were very confident this (expansion) was not going to result in any kind of erosion of the quality of the medical program.

As part of its expansion, the Med School introduced a new academy model of advising and training last year, with each class divided into three academies of around 40 students in order to facilitate greater advising services and a better sense of community. Each academy space provides locker and study space, designated advisers and other training services to students to help break down the student body into smaller sections.

Excerpt from:
Med school admits largest class ever

Med School admits largest class yet

The Alpert Medical School welcomed its largest class ever this year totalling 120 students following the opening of the schools downtown facility last fall. With the building constructed in downtown Providences Knowledge District able to accommodate more students, the school matriculated 11 additional students in this years class, up from 109 in the class of 2015. The school has expanded from 310 students in 2001 to 421 students this year, according to Ed Wing, dean of medicine and biological sciences.

The admittance of the Med Schools largest-ever class was made possible by the new facility, Wing said. Admitting classes of 120 will expand the school to 480 students in the next few years, he said.

Its a terrific building, Wing said, adding that the schools old space in the BioMedical Center did not allow for expansion. Everything in the (new) building has allowed us to provide better education.

The Med School also witnessed a surge in applications for spots in the class of 2016, with a roughly 20 percent increase from 2,825 applicants in 2011 to 3,344 applications in 2012, according to Philip Gruppuso, associate dean of medical education and professor of pediatrics.

There is in general a physician shortage in the United States, Gruppuso said. He noted that the Association of American Medical Colleges has called for a substantial increase in the countrys supply of doctors and that the University is hoping to aid this goal. Gruppuso said the Med Schools expansion was part of a long-term process that occurred after administrators received permission from the Liaison Committee on Medical Education, the national accrediting organization for medical degree programs.

Wing said administrators have nothing definite planned to expand the student body any further than 480 students.

The Med School hired more staff to accommodate the larger building, but they did not need to hire more faculty members, Wing said, adding that the school boasts a total of 2,000 faculty members, including 600 full-time clinical faculty. The Med School revamped its curriculum but did not add additional classes or expand the size of courses.

Gruppuso said the University is still considered a small medical school according to national rankings of medical degree programs by size.

We had space and resources and faculty to be able to meet the needs of this number of students, he said. We were very confident this (expansion) was not going to result in any kind of erosion of the quality of the medical program.

As part of its expansion, the Med School introduced a new academy model of advising and training last year, with each class divided into three academies of around 40 students in order to facilitate greater advising services and a better sense of community. Each academy space provides locker and study space, designated advisers and other training services to students to help break down the student body into smaller sections.

See original here:
Med School admits largest class yet

New gene offers hope for preventive medicine against fractures

Public release date: 18-Sep-2012 [ | E-mail | Share ]

Contact: Mattias Lorentzon, University of Gothenburg mattias.lorentzon@medic.gu.se 46-031-342-4929 University of Gothenburg

A big international study has identified a special gene that regulates bone density and bone strength. The gene can be used as a risk marker for fractures and opens up opportunities for preventive medicine against fractures. The study, led by the Sahlgrenska Academy, University of Gothenburg, Sweden, was published in the journal PLoS Genetics.

The international study, which involved more than 50 researchers from Europe, North America and Australia and was led by Associate Professor Mattias Lorentzon and Professor Claes Ohlsson at the Sahlgrenska Academy, University of Gothenburg, is based on extensive genetic analyses of the genetic material of 10,000 patients and experimental studies in mice.

Through the combined studies, researchers have succeeded in identifying a special gene, Wnt16, with a strong link to bone density and so-called cortical bone thickness, which is decisive to bone strength.

The genetic variation studied by the international research network could predict, for example, the risk of a forearm fracture in a large patient group of older women.

"In the experimental study, we could then establish that the gene had a crucial effect on the thickness and density of the femur. In mice without the Wnt16 gene, the strength of the femur was up to 61 per cent lower," according to Mattias Lorentzon at the Institute of Medicine, the Sahlgrenska Academy, University of Gothenburg.

The discovery opens up opportunities to develop new medicines to prevent the most common fractures.

"Low cortical bone mass is a decisive factor in, for example, hip and forearm fractures. Unfortunately, the treatments currently used for brittleness of the bones have very little effect on the cortical bone mass," says Mattias Lorentzon.

"If we can learn to stimulate the signaling routes of the Wnt16 gene, we could strengthen the skeleton in these parts too, thereby preventing the most common and serious fractures. The discovery of Wnt16 and its regulation of cortical bone mass is therefore very important," according to Mattias Lorentzon.

Read more from the original source:
New gene offers hope for preventive medicine against fractures

Sirona Biochem Hires Ray Matthews & Associates

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sep 18, 2012) - Sirona Biochem Corp. (TSX VENTURE:SBM)(SRBCF)(ZSB.F), a biotechnology company specializing in carbohydrate chemistry technology, is pleased to announce that it is has engaged Ray Matthews & Associates Inc. (RM&A) to provide corporate development and strategic advisory consulting services.

"Ray Matthews and his team have a proven track record in supporting financing efforts for several biotechnology companies," stated Dr. Howard Verrico, President & CEO of Sirona Biochem. "Ray Matthews and Associates joins Sirona Biochem at an exciting time with the company focused on partnering and commercialization. Our company will benefit from RM&A''s broad range of experience in strategic planning, corporate development, investor relations and operational consultation," Dr. Verrico added.

"In our first fund (Advantage), some of our early success was due to holdings which had novel solutions addressing blockbuster markets.Sirona Biochem has a compound in development which has the potential to achieve substantial shareholder value. I am excited to be able to add value and help attract additional talent and networks to advance this program," commented Ray Matthews.

About Sirona Biochem Corp.

Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients.The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. For more information, visit http://www.sironabiochem.com.

About Ray Matthews & Associates Inc.

Ray Matthews & Associates Inc (RM&A) is a strategic advisory firm focusing on corporate development, M&A, strategic planning and boutique IR services to Canadian and U.S.-based companies at all stages of development.For more information on RM&A Inc, please visit http://www.raymatthews.ca.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise.Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem''s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem''s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations.Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

More:
Sirona Biochem Hires Ray Matthews & Associates

A Biotechnology Firm Making Its First Step Towards Profitability?

By Declan Fallon - September 18, 2012 | Tickers: BIIB, ISIS | 0 Comments

Declan is a member of The Motley Fool Blog Network -- entries represent the personal opinions of our bloggers and are not formally edited.

As bullish markets expand, monies are channelled not just into established names, but to companies which offer the potential to become the next big names. In recent weeks, the number of stocks which have seen money flows above their typical average have markedly increased. Of these movers-and-shakers, one to make the grade was ISIS Pharmaceuticals (NASDAQ: ISIS).

ISIS Pharmaceuticals researches and develops antisense drugs, used for the treatment of cardiovascular, metabolic, severe and rare diseases, including cancer. The company focuses on Antisense RNA research. Antisense RNA operates like a blocker, preventing RNA (protein cooking instructions) from building proteins that may ultimately contribute or lead to disease. The company's business is to develop Antisense RNA-based drugs to a point where they can be licensed to a partner, who then commercialize it. The company has collaboration agreements with a number of companies, including Biogen Idec (NASDAQ: BIIB), Bristol-Myers Squibb, Eli Lilly,and GlaxoSmithKline.

Buyers regain momentum

ISIS Pharmaceuticals stock price has enjoyed a solid summer of 2012 after a few years of lackluster trading. The stock's nadir was 2009 when it ran into a $19 ceiling, and headed south to spend most of last year below $10 a share. But a couple of heavy trade days in early August following earnings, and more recently in September saw a shift from net selling to net buying. Largest was 3.3 million shares traded in a single day which was also so happened to come with a push above $14.

But income heavily tied to a single client

Like many biotechnology stocks, it has a variable but typically losing streak of earnings. Analyst expectations aren't a useful guide, although biotechnology stocks are probably less sensitive to earnings releases than perhaps other pharmaceutical companies which are less research focused. The company's revenues are heavily dependent on milestone payments from its research partners, Genzyme in particular. The Genzyme payments accounted for 90% and 84% of the $42.8 million and $59.1 million in reported revenue for the three and six months ended in June 30th 2012. ISIS almost squeaked a Q2 profit at a penny loss per share, although expectations for next quarter are for a $-0.28 loss.

Genzyme is working with ISIS Pharmaceuticals to develop its lead product, KYNAMRO, for the treatment of familial hypercholesterolemia. Commercialization can begin once it obtains the required regularly approval in Europe and the United States; the former application was made in June 2011, and latter to the FDA in May 2012. Submitting these applications generated a $25 payment from Genzyme. FDA approvals can take 6 to 10 months to complete, so it will be the latter part of the year until news of this is known. Should the FDA approve the commercial release of KYNAMRO then ISIS Pharmaceuticals will receive another $25 million payment from Genzyme. However, the larger picture is that ISIS Pharmaceuticals will have a new, more substantial, source of revenue in the form of license payments, not to mention a milestone payment of up to $825 million for commercialization of the drug.

However, it has more than one string to its bow

Go here to see the original:
A Biotechnology Firm Making Its First Step Towards Profitability?

BioSpain 2012 is Larger in Terms of Internationalisation and the Number of Exhibitors, Meetings and Visitors

MADRID, September 18, 2012 /PRNewswire/ --

6th International Meeting on Biotechnology to be held atBilbao Exhibition Centre (BEC), in Barakaldo (Bilbao), from 19 to 21 September

The figures gathered to date by the BioSpain 2012 organisation show the event will be a major success and evidence the growing importance of biotechnology in Spain.

The 6th International Meeting on Biotechnology, BioSpain 2012 (http://www.biospain2012.org)-a biennial event, is organised by ASEBIO, the Spanish Association of Biotechnology Companies, in cooperation with Society for Competitive Transformation (SPRI), an agency of the Basque government, this year. BioSpain 2012 will run from 19 to 21 September in Bilbao Exhibition Centre (BEC), in Barakaldo.

International participants account for 30% of the total and twenty-five countries are represented at the event. The main countries, in terms of both participation and exhibition space, are the UK, the US, France, Germany, Mexico, Switzerland, Sweden, Belgium and the Netherlands.

The trade fair is fully booked with 216 exhibitors. The event will attract 1,450 professional visitors and 750 companies.

Also, the space for partnering/business development meetings provides room for up to 4,500 one-on-one meetings. That figure would place BioSpain in fourth place among the world's biotech business development events (from 7th place at present).

Regina Revilla, President of ASEBIO, considers that these figures evidence the importance of biotechnology in Spain. "We are very proud of the response on the part of our companies and institutions, and of the great interest that BioSpain 2012 has aroused, considering the large number of interesting biotech events in other countries. We are confident that BioSpain 2012 will fulfil participants' business expectations and help develop the industry in Spain".

A new feature of BioSpain 2012 is the biotechnology Career Fair, which will enable students and professionals to interface with companies and academic institutions in order to explore employment and training opportunities.

BioSpain 2012 also includes an Investment Forum. A total of 32 projects have been presented and will be assessed by a panel of Spanish and international experts. Other features include breakout sessions and Biotec 2012, the scientific conference of the Spanish Society of Biotechnology (SEBIOT).

Read more here:
BioSpain 2012 is Larger in Terms of Internationalisation and the Number of Exhibitors, Meetings and Visitors

Wiley signs collaboration agreement with the Asian Federation of Biotechnology

Public release date: 18-Sep-2012 [ | E-mail | Share ]

Contact: Ben Norman Sciencenewsroom@wiley.com 44-012-437-70375 Wiley

Weinheim, Germany. September 18, 2012. John Wiley & Sons, Inc., has announced the signing of a new collaboration agreement between Biotechnology Journal and the Asian Federation of Biotechnology (AFOB). From 2013 the Federation will contribute two special issues to the journal annually, while representatives from the AFOB will join the editorial board.

Since launching in 2006 Biotechnology Journal has become a truly international title. Edited by Professor Sang Yup Lee, from KAIST University in South Korea, and Professor Alois Jungbauer from BOKU University in Austria, the journal attracts international authors, a global readership and will be awarded an official Impact Factor in 2013.

As a partner journal of the AFOB, the Biotechnology Journal will work with the Federation to disseminate scientific knowledge from Asian research communities to a global audience by dedicating special issues to research and breakthroughs on topics that are relevant to all biotechnologists.

A new "AFOB Highlights" section will also be introduced to the journal as a forum for reporting Federation news, announcements, prizes and awards.

The AFOB will also contribute news and views to Wiley's BiotecVisions e-magazine, which will be circulated to all Federation members on a monthly basis.

Biotechnology Journal will continue to collaborate with the European Federation of Biotechnology section on Biochemical Engineering, placing it in a unique position to serve as a bridge between European and Asian biotechnologists.

"Wiley's mission is to bring the best of science to an international audience," said Carol Bacchus, Vice President and Publishing Director, Life Sciences, Wiley. "This AFOB collaboration is a new milestone, which will foster greater international co-operation between Asian and non-Asian scientists to enhance our knowledge in all areas and applications of biotechnology and engineering technologies."

"Working with Biotechnology Journal has always been a pleasurable and successful experience for the AFOB," said Professor Ho Nam Chang, AFOB's incoming president. "We are therefore delighted to have this official agreement, which will further promote research from Asia to an international audience."

Read this article:
Wiley signs collaboration agreement with the Asian Federation of Biotechnology

DNA2.0 Taps VTU Technology as Research Partner for Industrial Scale Protein Expression

MENLO PARK, Calif. & GRAMBACH/GRAZ, Austria--(BUSINESS WIRE)--

DNA2.0, the leading bioengineering solutions provider and VTU Technology, the leader in Pichia pastoris protein expression services, today announced a partnership to develop and refine a gene design algorithm to enable maximized protein production in the yeast P. pastoris. The collaboration will combine VTUs deep P. pastoris expertise and AOX1 promoter technology with DNA2.0s gene design technology for robust translation.

Pichia is ideally suited for high-level expression of recombinant proteins for therapeutic and industrial applications, said Dr. Thomas Purkarthofer, Head of Business Development of VTU Technology. We are excited to merge the unparalleled strength of our P. pastoris expression system with DNA2.0s industry-leading gene design and expression optimization technology.

VTUs P. pastoris protein expression platform is based on engineered versions of the AOX1 promoter, one of the strongest eukaryotic promoters known. VTUs approach delivers up to 20 g/L of secreted protein within a few weeks development time, and the company has a proven track record for expressing commercial levels of a wide range of proteins including serum proteins, cytokines, fusion proteins, Fabs, antibody derived fragments, scaffold proteins and enzymes.

The protein target for this collaboration is DNA2.0s IP-free CometGFP, which is part of a novel family of fluorescent and colorimetric proteins developed by DNA2.0. The corresponding IP-free genes are brought to market without expensive, constrained licensing.

We developed our initial Pichia gene design algorithm with the world-leading P. pastoris laboratory of Anton Glieder, and we are thrilled to expand the breadth and scope of our P. pastoris technology for industrial scale applications with the proven commercial leader in the field, VTU Technology, said Jeremy Minshull, Ph.D., cofounder and CEO of DNA2.0. Controllable, consistent and strong protein expression is the goal regardless of the type of research in which you are engaged, and our patented GeneGPS technology has been proven to produce orders of magnitude increases in protein expression.

About VTU Technology:

VTU Technology is a leading provider of comprehensive services based on exclusive and innovative Pichia pastoris protein production technologies. With exclusive know-how and extensive experience, VTUs skilled team delivers fast-track development of high-performance industrial protein production strains enabling high expression yields and economically attractive production processes.

Headquartered in Grambach/Graz, Austria, VTU Technology is a private company and a subsidiary ofVTU Holding, an Austrian enterprise that combines several technology and engineering companies in chemistry, pharma & life science as well as power and fuel industries. For more information, please visit http://www.vtu-technology.com

About DNA2.0:

View post:
DNA2.0 Taps VTU Technology as Research Partner for Industrial Scale Protein Expression

Travelocity Announces Winners of Travel For Good Voluntourism Grants

SOUTHLAKE, Texas--(BUSINESS WIRE)--

Travelocity is committed to making the world a better place one trip at a time, and this week the company gave three winners of their Travel For Good Contest the chance to do the same by awarding them each a $5,000 voluntourism grant. Entrants of the contest were required to create a two-minute video telling Travelocity why they would like to experience one of eight signature voluntourism trips, ranging from wildlife research on the Amazon River, to educating local children in South America.

We had people from all walks of life apply for the Travel for Good grants, said Travelocity President & CEO, Carl Sparks. Students, parents, health professionals and artists impressed us with their love of travel and passion for giving back, and we are extremely excited about the three winners we have selected.

The Winners of the Travelocity Travel for Good Grants (Summer 2012):

Talia, a student in Long Island, is going to Brazil to help make a difference in childrens lives, working to improve quality care in under-sourced and overcrowded community centers and daycares. As she said in her song, Were one small part of the world one grain of sand on the beach swept together with the winds of change something bigger is in our reach.

Allie, a recent public health graduate, is going to Tanzania to focus on fighting the HIV/AIDS stigma in Africa. This is a continued passion that began while she attended Oregon State University, where she learned how to improve the populations health through education and prevention.

Aaron, a health educator, is going to Brazil to give marginalized populations affected by HIV/AIDS a voice to tell their stories and create platforms for change.

About Travelocitys Travel For Good

Travelocitys Travel for Good (http://www.travelocity.com/travelforgood) program is dedicated to making the world a better place through travel. We believe we can uphold our responsibility of making the world a better place by helping the destinations we love to visit while we're there, and by helping travelers minimize the environmental impact of their journeys. Started by Travelocity employees, the program offers travelers green travel options including carbon offsets, a Green Hotel directory and the option to rent a hybrid car, as well as Green Vacation and Voluntourism ideas. Each year, Travelocitys Travel For Good rewards travelers and employees with $5,000 voluntourism grants to give back to deserving communities around the world.

Read more here:

Travelocity Announces Winners of Travel For Good Voluntourism Grants

India not to undertake human space flight before 2017: ISRO

Bangalore:India will not undertake a human space flight before the year 2017 and is likely to use a next-generation rocket for the ambitious mission, the cost of which would be reworked, Chairman of Indian Space Research Organisation K Radhakrishnan said on Monday.

Mr Radhakrishnan, also Department of Space Secretary and Space Commission Chairman, confirmed that the venture is not part of the 12th five-year plan (2012-2017). However, he said that there are funds to continue with pre-project studies and develop critical technologies associated with the proposed mission.

ISRO officials noted that the space agency currently does not have an operational GSLV, after two unsuccessful missions, one with Indian cryogenic engine and another with the imported Russian one in 2010.

Mr Radhakrishnan said GSLV with indigenous cryogenic engine and stage would be flight-tested in January-February next year.

"If you look at the scenario today, we do not have a programme (human space flight) declared as such (yet to get Cabinet approval)", he told reporters in response to questions. ISRO's proposed human space flight programme was much talked about in the second half of the last decade. However, the twin-failures of the GSLV saw to it that it lost momentum. In 2008-09, it was estimated that a sum of Rs 12,400 crore would be required for undertaking the mission. "We need to rework (on that figure)", Mr Radhakrishnan said.

GSLV-Mk II (rocket) was proposed to be used for the mission then, but Mr Radhakrishnan on Monday said it would be able to carry a two-member crew only, while GSLV-Mk III which is under development would have additional mass left for conducting scientific experiments besides a two-member crew.

"We feel it (GSLV-Mk III) would be a better vehicle (for the mission)", he said.

Mr Radhakrishnan, however, said ISRO already has a budget of Rs 150 crore for conducting pre-project studies and developing critical technologies including environmental control, space suit, reentry and crew escape system. The rocket must have man-rating, he noted.

The mission is aimed at building and demonstrating the capability for carrying humans to low earth orbit and their safe return to earth.

In the year 2008, the buzz was that India would likely to have the human space flight during 2014-15, which now appears to be surely missed.

See original here:

India not to undertake human space flight before 2017: ISRO

Caraway City Council paid tribute to All American Red Heads

The Caraway city council paid tribute to the All American Red Heads for their national honor and made plans for new Fire Department building and street repairs at the council meeting held Thursday, Sept. 13.

The city proclaimed Sept. 7 as American Red Heads Day in recognition of them being named into the Naismith Memorial Basketball Hall of Fame, in Springfield Mass. The team's home base was in Caraway while owned and managed by Orwell Moore.

The council voted to hire an architect to complete work on the new Fire Department building.

"The application for the $50,000 grant is due by Nov. 1," Mayor Barry Riley said. "It is a requirement that we use an architect. His fee is 10 percent of the grant money received and will be taken out of the grant itself."

Riley reviewed estimates in constructing the building which could run from $86,000 to $100,000 overall.

The council discussed plans for the ongoing main street resurfacing project, which involves removal of all old asphalt (12 inches in height) and laying a three-inch layer of new asphalt, to allow proper drainage downtown. The main street area involves pavement from New York Street to St. Louis Street and includes work on eight-inch water lines and four water hydrants.

Bid received on the project included $115,000 from API Asphalt of Jonesboro and $125,550 from Atlas Asphalt Inc. of Jonesboro.

The Craighead County Road Department has agreed to remove the excess asphalt and make repairs on the roadbed.

Terry (Couch) will have two people helping him with the water lines and hydrants," Riley said. "This will save us a lot of money.

"All street corrections to entrances and exits along main street will be taken care of. The expenses would come out of the General Fund and sales tax accounts. We are looking at the cost with hopes of starting in the spring."

Read more here:

Caraway City Council paid tribute to All American Red Heads

New gene offers hope for preventive medicine against fractures

Public release date: 18-Sep-2012 [ | E-mail | Share ]

Contact: Mattias Lorentzon, University of Gothenburg mattias.lorentzon@medic.gu.se 46-031-342-4929 University of Gothenburg

A big international study has identified a special gene that regulates bone density and bone strength. The gene can be used as a risk marker for fractures and opens up opportunities for preventive medicine against fractures. The study, led by the Sahlgrenska Academy, University of Gothenburg, Sweden, was published in the journal PLoS Genetics.

The international study, which involved more than 50 researchers from Europe, North America and Australia and was led by Associate Professor Mattias Lorentzon and Professor Claes Ohlsson at the Sahlgrenska Academy, University of Gothenburg, is based on extensive genetic analyses of the genetic material of 10,000 patients and experimental studies in mice.

Through the combined studies, researchers have succeeded in identifying a special gene, Wnt16, with a strong link to bone density and so-called cortical bone thickness, which is decisive to bone strength.

The genetic variation studied by the international research network could predict, for example, the risk of a forearm fracture in a large patient group of older women.

"In the experimental study, we could then establish that the gene had a crucial effect on the thickness and density of the femur. In mice without the Wnt16 gene, the strength of the femur was up to 61 per cent lower," according to Mattias Lorentzon at the Institute of Medicine, the Sahlgrenska Academy, University of Gothenburg.

The discovery opens up opportunities to develop new medicines to prevent the most common fractures.

"Low cortical bone mass is a decisive factor in, for example, hip and forearm fractures. Unfortunately, the treatments currently used for brittleness of the bones have very little effect on the cortical bone mass," says Mattias Lorentzon.

"If we can learn to stimulate the signaling routes of the Wnt16 gene, we could strengthen the skeleton in these parts too, thereby preventing the most common and serious fractures. The discovery of Wnt16 and its regulation of cortical bone mass is therefore very important," according to Mattias Lorentzon.

Here is the original post:

New gene offers hope for preventive medicine against fractures

Med school admits largest class ever

The Alpert Medical School welcomed its largest class ever this year totalling 120 students following the opening of the schools downtown facility last fall. With the building constructed in downtown Providences Knowledge District able to accommodate more students, the school matriculated 11 additional students in this years class, up from 109 in the class of 2015. The school has expanded from 310 students in 2001 to 421 students this year, according to Ed Wing, dean of medicine and biological sciences.

The admittance of the Med Schools largest-ever class was made possible by the new facility, Wing said. Admitting classes of 120 will expand the school to 480 students in the next few years, he said.

Its a terrific building, Wing said, adding that the schools old space in the BioMedical Center did not allow for expansion. Everything in the (new) building has allowed us to provide better education.

The Med School also witnessed a surge in applications for spots in the class of 2016, with a roughly 20 percent increase from 2,825 applicants in 2011 to 3,344 applications in 2012, according to Philip Gruppuso, associate dean of medical education and professor of pediatrics.

There is in general a physician shortage in the United States, Gruppuso said. He noted that the Association of American Medical Colleges has called for a substantial increase in the countrys supply of doctors and that the University is hoping to aid this goal. Gruppuso said the Med Schools expansion was part of a long-term process that occurred after administrators received permission from the Liaison Committee on Medical Education, the national accrediting organization for medical degree programs.

Wing said administrators have nothing definite planned to expand the student body any further than 480 students.

The Med School hired more staff to accommodate the larger building, but they did not need to hire more faculty members, Wing said, adding that the school boasts a total of 2,000 faculty members, including 600 full-time clinical faculty. The Med School revamped its curriculum but did not add additional classes or expand the size of courses.

Gruppuso said the University is still considered a small medical school according to national rankings of medical degree programs by size.

We had space and resources and faculty to be able to meet the needs of this number of students, he said. We were very confident this (expansion) was not going to result in any kind of erosion of the quality of the medical program.

As part of its expansion, the Med School introduced a new academy model of advising and training last year, with each class divided into three academies of around 40 students in order to facilitate greater advising services and a better sense of community. Each academy space provides locker and study space, designated advisers and other training services to students to help break down the student body into smaller sections.

Read the original:

Med school admits largest class ever